MRI-invisible lesions and low-risk prostate cancer скачать в хорошем качестве

MRI-invisible lesions and low-risk prostate cancer

Can prostate cancers be seen by pathologists in biopsies but invisible on MRIs? Yes they can, and what does it mean? Dr, Mark Emberton, Professor of Interventional oncology at University College London and Dean of its Faculty of Medical Sciences, spoke at the ASPI webinar on Saturday, January 25, 2025. Emberton is a pioneer on the use of MRIs in diagnosing, classifying and monitoring prostate cancer. Professor Emberton’s clinical research is aimed at improving the diagnostic and risk stratification tools and treatment strategies for prostate cancer (PCa). He specializes in the implementation of new imaging techniques, nanotechnologies, bio-engineering materials and non-invasive treatment approaches, such as high intensity focused ultrasound and photo-dynamic therapy. His research has been published in over 300 peer-reviewed scientific papers in journals including BMJ, Lancet Oncology and European Urology. He has also contributed to the development of guidelines for the management of PCa and lower urinary tract symptoms, published by the International Society of Geriatric Oncology and the European Association of Urology. 3:35 Dr. Emberton 42:02 Q & A 1:00:19 Open forum